vs
Side-by-side financial comparison of MAXLINEAR, INC (MXL) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
MAXLINEAR, INC is the larger business by last-quarter revenue ($137.2M vs $70.6M, roughly 1.9× Viridian Therapeutics, Inc.\DE). MAXLINEAR, INC runs the higher net margin — -32.9% vs -49.0%, a 16.1% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 43.0%).
MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
MXL vs VRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $137.2M | $70.6M |
| Net Profit | $-45.1M | $-34.6M |
| Gross Margin | 57.5% | — |
| Operating Margin | 30.0% | -56.7% |
| Net Margin | -32.9% | -49.0% |
| Revenue YoY | 43.0% | 81958.1% |
| Net Profit YoY | -203.0% | 54.9% |
| EPS (diluted) | $-0.52 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $137.2M | — | ||
| Q4 25 | $136.4M | — | ||
| Q3 25 | $126.5M | $70.6M | ||
| Q2 25 | $108.8M | — | ||
| Q1 25 | $95.9M | — | ||
| Q4 24 | $92.2M | — | ||
| Q3 24 | $81.1M | — | ||
| Q2 24 | $92.0M | — |
| Q1 26 | $-45.1M | — | ||
| Q4 25 | $-14.9M | — | ||
| Q3 25 | $-45.5M | $-34.6M | ||
| Q2 25 | $-26.6M | — | ||
| Q1 25 | $-49.7M | — | ||
| Q4 24 | $-57.8M | — | ||
| Q3 24 | $-75.8M | — | ||
| Q2 24 | $-39.3M | — |
| Q1 26 | 57.5% | — | ||
| Q4 25 | 57.6% | — | ||
| Q3 25 | 56.9% | — | ||
| Q2 25 | 56.5% | — | ||
| Q1 25 | 56.1% | — | ||
| Q4 24 | 55.6% | — | ||
| Q3 24 | 54.4% | — | ||
| Q2 24 | 54.6% | — |
| Q1 26 | 30.0% | — | ||
| Q4 25 | -10.9% | — | ||
| Q3 25 | -32.7% | -56.7% | ||
| Q2 25 | -22.6% | — | ||
| Q1 25 | -48.0% | — | ||
| Q4 24 | -44.7% | — | ||
| Q3 24 | -82.3% | — | ||
| Q2 24 | -44.4% | — |
| Q1 26 | -32.9% | — | ||
| Q4 25 | -10.9% | — | ||
| Q3 25 | -36.0% | -49.0% | ||
| Q2 25 | -24.4% | — | ||
| Q1 25 | -51.8% | — | ||
| Q4 24 | -62.8% | — | ||
| Q3 24 | -93.4% | — | ||
| Q2 24 | -42.7% | — |
| Q1 26 | $-0.52 | — | ||
| Q4 25 | $-0.17 | — | ||
| Q3 25 | $-0.52 | — | ||
| Q2 25 | $-0.31 | — | ||
| Q1 25 | $-0.58 | — | ||
| Q4 24 | $-0.68 | — | ||
| Q3 24 | $-0.90 | — | ||
| Q2 24 | $-0.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $61.1M | $490.9M |
| Total DebtLower is stronger | $123.8M | — |
| Stockholders' EquityBook value | $454.2M | $503.0M |
| Total Assets | $771.3M | $577.1M |
| Debt / EquityLower = less leverage | 0.27× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $61.1M | — | ||
| Q4 25 | $72.8M | — | ||
| Q3 25 | $111.9M | $490.9M | ||
| Q2 25 | $108.6M | — | ||
| Q1 25 | $102.8M | — | ||
| Q4 24 | $118.6M | — | ||
| Q3 24 | $148.5M | — | ||
| Q2 24 | $185.1M | — |
| Q1 26 | $123.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $454.2M | — | ||
| Q4 25 | $451.9M | — | ||
| Q3 25 | $464.7M | $503.0M | ||
| Q2 25 | $488.3M | — | ||
| Q1 25 | $493.2M | — | ||
| Q4 24 | $516.3M | — | ||
| Q3 24 | $556.9M | — | ||
| Q2 24 | $617.3M | — |
| Q1 26 | $771.3M | — | ||
| Q4 25 | $796.4M | — | ||
| Q3 25 | $808.1M | $577.1M | ||
| Q2 25 | $863.7M | — | ||
| Q1 25 | $855.3M | — | ||
| Q4 24 | $864.6M | — | ||
| Q3 24 | $895.3M | — | ||
| Q2 24 | $973.2M | — |
| Q1 26 | 0.27× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.4M | — | ||
| Q3 25 | $10.1M | $-84.6M | ||
| Q2 25 | $10.5M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | $-27.8M | — | ||
| Q3 24 | $-30.7M | — | ||
| Q2 24 | $-2.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $6.7M | — | ||
| Q3 25 | $4.4M | $-84.7M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $-13.4M | — | ||
| Q4 24 | $-30.0M | — | ||
| Q3 24 | $-34.9M | — | ||
| Q2 24 | $-5.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | — | ||
| Q3 25 | 3.5% | -120.1% | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -14.0% | — | ||
| Q4 24 | -32.6% | — | ||
| Q3 24 | -43.0% | — | ||
| Q2 24 | -6.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 4.5% | 0.2% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 3.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
